Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Potential risk of second primary tumours
2011.04.01
Active substance: lenalidomide
Important information on the potential risk of second primary tumours in patients treated with Revlimid® (lenalidomide).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN